Clinical trial · Interventional
Phase 1 Study of BIIB022 (Anti-IGF-1R Monoclonal Antibody) in Relapsed/Refractory Solid Tumors
A Phase 1, Open Label, Dose Escalation Study of BIIB022 (Anti-IGF-1R Monoclonal Antibody) in Subjects With Relapsed or Refractory Solid Tumors
NCT00555724CI-TRIAL-00025408completedPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Phase 1, open-labeled, dose escalation safety and tolerability study for the treatment of subjects with relapsed or refractory solid tumors.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Solid Tumors | Solid Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| BIIB022 | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- BIIB022
- interventionNames
- Drug: BIIB022
Primary outcomes (1)
- measure
- To evaluate the safety and tolerability of BIIB022
- timeFrame
- ongoing
Secondary outcomes (1)
- measure
- To evaluate pharmacokinetics
- timeFrame
- ongoing
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age 18 years or older at the time of informed consent * Relapsed or refractory solid tumors following standard therapy. * ECOG Performance Status 0 or 1. Exclusion Criteria: * History of insulin-dependent diabetes, type 2 diabetes, or hemoglobin A1c \>6% at screening. * History of myocardial infarction within 12 months prior to Day 1 or chronic heart failure. * Known central nervous system or brain metastases. * Prior anti-IGF-1R therapy of any kind. Other protocol-defined inclusion/exclusion criteria may apply.
References
Publications (1)
- BACKGROUNDvon Mehren M, Britten CD, Pieslor P, Saville W, Vassos A, Harris S, Galluppi GR, Darif M, Wainberg ZA, Cohen RB, Leong S. A phase 1, open-label, dose-escalation study of BIIB022 (anti-IGF-1R monoclonal antibody) in subjects with relapsed or refractory solid tumors. Invest New Drugs. 2014 Jun;32(3):518-25. doi: 10.1007/s10637-014-0064-y. Epub 2014 Jan 24. PMID 24458261